DeepIntent opens live sports CTV to pharma with verified inventory suite

Pharmaceutical brands have historically avoided live sports streaming due to unreliable bidstream signals and a lack of clinical outcome measurement. This launch establishes the first technical framework that handles both the high-latency requirements of live ad pacing and the strict regulatory demands of healthcare identity graphing. By moving inventory transparency upstream through PMP structures, DeepIntent enables pharma to compete for premium moments like the World Cup and NFL Playoffs with the same deterministic rigor used in stationary digital channels. Watch for whether this infrastructure successfully poaches the remaining 12% of pharma spend still tied to broad-reach linear TV as digital formats reach 82% of category spend by 2027.

The shift toward live CTV arrives as pharmaceutical digital ad spending is projected to reach $26.2 billion in 2026, significantly outpacing the $6.9 billion remaining in traditional channels, per eMarketer and Fierce Pharma. While linear TV still plays a role in drug launches and broad awareness, its share of the healthcare category is forecast to drop to just 12% by 2027. This industry-wide migration has forced a rethinking of how 'reach' is valued; data from iSpot.tv in late 2025 showed that while linear spend grew by 16%, household impressions only rose 7%, signaling that brands are paying significantly more for a shrinking traditional audience pool.

DeepIntent's infrastructure play follows its March 2026 launch of Helix, a HIPAA-compliant marketing cloud spanning 240 million patient lives. Per solli, early Helix partners reported a 50% increase in workflow speed by utilizing pre-integrated health data. This centralization of identity and clinical data is becoming a competitive necessity as the FDA increases regulatory scrutiny on direct-to-consumer advertising. Platforms that can unify these datasets with the volatile demand of live sports streaming are effectively building the transition path for top-spending immunology and weight-loss brands, which collectively spent over $323 million in a single month during the NFL-led advertising windows of early 2026.